A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03):

Clinical Trial Grant

Duke Scholars

Principal Investigator Michael Roger Harrison Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

August 13, 2021

End Date

August 30, 2025

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

August 13, 2021

End Date

August 30, 2025